MEDBOT-B has announced its annual results for the period ending December 31, 2025. The company recorded revenue of 551 million yuan, an increase of 114.2% year-on-year. Gross profit was 267 million yuan, up 209.2% compared to the previous year. The pre-tax loss stood at 254 million yuan, a reduction of 60.7% from the prior year. The net loss for the year was also 254 million yuan, decreasing by 60.7% year-on-year. The adjusted net loss was 165 million yuan, down 65.8% from the previous year. Loss per share was 0.24 yuan, a 63.6% improvement from the 0.66 yuan loss per share reported a year earlier. The significant improvement in performance was primarily driven by a breakthrough in the commercialization of the company's core product, the Toumai laparoscopic surgical robot. Notably, sales growth in overseas markets was substantial, with over 100 new orders secured internationally during the year. Revenue from overseas markets was more than five times the figure from the previous year, demonstrating strong global expansion momentum. Management highlighted that, benefiting from revenue growth, strategic focus, and the successful implementation of cost-reduction and efficiency measures, free cash flow achieved a net inflow in the second half of 2025. In terms of business segments, the company's primary revenue sources are the sales of surgical robot systems, instruments, and accessories, as well as the provision of services. The proportion of sales from overseas markets increased to 73%, becoming the core driver of revenue growth. Overall, the company's global market presence and product commercialization have shown significant progress, particularly in the surgical robotics sector, highlighting strong market competitiveness and sustainable development potential.